LATEST ANNOUNCEMENT

Ascend Announces Patients with Nodular Basal Cell Carcinoma receives first dose of ASN-002 in Phase 1/2a Study

5th October 2015: Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company focused on developing innovative cancer therapeutics, today announced the first nodular Basal Cell Carcinoma patient (nBCC) dosed with ASN-002 (an injectable immunotherap